# Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors

> **NCT05098847** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Liver Metastasis

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Lenvatinib
- **DRUG:** Cryoablation

## Key facts

- **NCT ID:** NCT05098847
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-29
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098847, "Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05098847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*